Liao Xiang-Wei, Ling Yun, Li Xin-Hua, Han Yue, Zhang Shen-Ying, Gu Lei-Lei, Yu De-Ming, Yao Bi-Lian, Zhang Dong-Hua, Jin Gen-Di, Lu Zhi-Meng, Gong Qi-Ming, Zhang Xin-Xin
Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, China.
Antivir Ther. 2011;16(2):141-7. doi: 10.3851/IMP1703.
Genome-wide association studies have recently shown that the rs12979860 polymorphism in IL28B is associated with the response to chronic hepatitis C treatment. The aim of this study was to investigate whether rs12979860 could be used as a predictive marker for end-of-treatment response (ETR) or sustained virological response (SVR) in the Chinese Han population.
The rs12979860 genotype was detected in 259 individuals infected with HCV by DNA sequencing. Among them, 120 patients were administered complete pegylated interferon-α and ribavirin combination therapy and 92 patients were followed for 24 weeks after the cessation of treatment and were divided into different groups according to outcomes of treatment.
The rs12979860 genotype CC was the primary genotype (87.64%, 227/259) and genotype TT was found in only one individual within this cohort. The patients with the rs12979860 genotype CC had higher rates of ETR (P=0.0044) and SVR (P=0.0046) than the patients with N-CC (CT or TT). In multivariate analyses, the rs12979860 genotype CC was associated with a substantial difference in rates of achieving ETR (odds ratio [OR] 8.983, 95% confidence interval [CI] 2.173-37.145; P=0.0024) and SVR (OR 24.298, 95% CI 2.27-259.90; P=0.0083).
This study demonstrated for the first time that the rs12979860 variation in IL28B could be a predictor of ETR and SVR in Chinese Han patients infected with HCV. The high frequency of the rs12979860 genotype CC might explain why the SVR rate is higher than that of the average global population.
全基因组关联研究最近表明，IL28B基因中的rs12979860多态性与慢性丙型肝炎治疗反应相关。本研究的目的是调查rs12979860是否可作为中国汉族人群治疗结束反应（ETR）或持续病毒学应答（SVR）的预测标志物。
通过DNA测序检测了259例HCV感染者的rs12979860基因型。其中，120例患者接受了完整的聚乙二醇化干扰素-α和利巴韦林联合治疗，92例患者在治疗停止后随访24周，并根据治疗结果分为不同组。
rs12979860基因型CC是主要基因型（87.64%，227/259），该队列中仅在1例个体中发现基因型TT。rs12979860基因型CC的患者比非CC（CT或TT）患者具有更高的ETR率（P=0.0044）和SVR率（P=0.0046）。在多变量分析中，rs12979860基因型CC与实现ETR的率有显著差异相关（优势比[OR]8.983，95%置信区间[CI]2.173-37.145；P=0.0024）和SVR（OR 24.298，95%CI 2.27-259.90；P=0.0083）。
本研究首次证明，IL28B基因中的rs12979860变异可能是中国汉族HCV感染患者ETR和SVR的预测指标。rs12979860基因型CC的高频率可能解释了SVR率高于全球平均水平的原因。
